Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aerpio's Tie2 activator fails diabetic retinopathy trial

Aerpio said twice-daily 15 mg subcutaneous AKB-9778 missed the primary endpoint in the Phase

Read the full 146 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE